Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Osteoporosis
Interventions
DRUG

Raloxifene

DRUG

Zoledronic acid

DRUG

Placebo oral pills

DRUG

Placebo intravenous (i.v.) infusion

Trial Locations (17)

10032

Columbia University, New York

20036

Washington D.C.

27215

Kernodle Clinic, Inc., Burlington

32216

Jacksonville Center for Clinical Research, Jacksonville

32256

Women's Physicians of Jacksonville, Jacksonville

33624

Tampa Clinical Research, Tampa

62703

Springfield Clinic, Springfield

63131

Consultants in Women's Health Care, St Louis

68152

Alegent Health, Omaha

76104

Texas Institute for Clinical Research, Fort Worth

85015

Women's Health Research, Phoenix

89048

Specialty Medical and Research Center, Pahrump

90620

Associated Pharma Research Center, Buena Park

97205

The Portland Clinic, Portland

97239

Oregon Health and Science University, Portland

98055

Valley Women's Health Clinic, Renton

08901

UMDNJ-Robert Wood Johnson Medical Center, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY